MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- BIOCON - ADCOCK INGRAM (S. Africa)
BIOCON vs ADCOCK INGRAM (S. Africa) - Comparison Results
BIOCON Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 BIOCON  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-19 |
ADCOCK INGRAM Jun-14 |
BIOCON / ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 707 | 381 | - | |
| Low | Rs | 554 | 275 | - | |
| Sales per share (Unadj.) | Rs | 91.9 | 113.2 | - | |
| Earnings per share (Unadj.) | Rs | 16.7 | -28.5 | - | |
| Cash flow per share (Unadj.) | Rs | 24.2 | -23.6 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 101.6 | 88.9 | - | |
| Shares outstanding (eoy) | m | 600.00 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 6.9 | 2.9 | 237.1% | |
| Avg P/E ratio | x | 37.7 | -11.5 | -328.6% | |
| P/CF ratio (eoy) | x | 26.1 | -13.9 | -188.3% | |
| Price / Book Value ratio | x | 6.2 | 3.7 | 168.3% | |
| Dividend payout | % | 6.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 378,330 | 55,292 | 684.2% | |
| No. of employees | `000 | 6.1 | 4.3 | 142.8% | |
| Total wages/salary | Rs m | 11,653 | 3,470 | 335.8% | |
| Avg. sales/employee | Rs Th | 8,994.3 | 4,451.4 | 202.1% | |
| Avg. wages/employee | Rs Th | 1,900.7 | 808.4 | 235.1% | |
| Avg. net profit/employee | Rs Th | 1,635.3 | -1,121.7 | -145.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 55,144 | 19,110 | 288.6% | |
| Other income | Rs m | 1,444 | 134 | 1,079.0% | |
| Total revenues | Rs m | 56,588 | 19,244 | 294.1% | |
| Gross profit | Rs m | 15,883 | -3,312 | -479.6% | |
| Depreciation | Rs m | 4,478 | 825 | 542.9% | |
| Interest | Rs m | 709 | 518 | 137.0% | |
| Profit before tax | Rs m | 12,140 | -4,520 | -268.6% | |
| Minority Interest | Rs m | 9 | -13 | -71.4% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,123 | 282 | 751.6% | |
| Profit after tax | Rs m | 10,026 | -4,815 | -208.2% | |
| Gross profit margin | % | 28.8 | -17.3 | -166.2% | |
| Effective tax rate | % | 17.5 | -6.2 | -279.9% | |
| Net profit margin | % | 18.2 | -25.2 | -72.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 48,228 | 13,997 | 344.6% | |
| Current liabilities | Rs m | 30,376 | 7,875 | 385.7% | |
| Net working cap to sales | % | 32.4 | 32.0 | 101.1% | |
| Current ratio | x | 1.6 | 1.8 | 89.3% | |
| Inventory Days | Days | 68 | 111 | 61.6% | |
| Debtors Days | Days | 86 | 124 | 69.0% | |
| Net fixed assets | Rs m | 64,130 | 8,159 | 786.1% | |
| Share capital | Rs m | 3,000 | 89 | 3,381.2% | |
| Net worth | Rs m | 60,980 | 14,999 | 406.6% | |
| Long term debt | Rs m | 15,766 | 5,271 | 299.1% | |
| Total assets | Rs m | 121,924 | 28,335 | 430.3% | |
| Interest coverage | x | 18.1 | -7.7 | -234.4% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 73.6% | |
| Sales to assets ratio | x | 0.5 | 0.7 | 67.1% | |
| Return on assets | % | 8.8 | -15.2 | -58.0% | |
| Return on equity | % | 16.4 | -32.1 | -51.2% | |
| Return on capital | % | 16.8 | -19.8 | -84.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 11,546 | 1,631 | 707.8% | |
| From Investments | Rs m | -7,138 | -501 | 1,425.2% | |
| From Financial Activity | Rs m | -2,417 | 4,784 | -50.5% | |
| Net Cashflow | Rs m | 2,103 | 5,914 | 35.6% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.25 Rs / ZAR
Compare BIOCON With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare BIOCON With: PFIZER ABBOTT INDIA FDC NATCO PHARMA SUN PHARMA
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)
Jan 25, 2021 | Updated on Jan 25, 2021For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Warning About Bubbles (Fast Profits Daily)
Apr 16, 2021Those who don't learn from financial history are doomed to lose their money.
More
